ABIOMED Financial Statements (ABMD)
|
|
|
|
Report date
|
|
|
20.05.2022 |
04.08.2022 |
03.11.2022 |
|
03.11.2022 |
|
Currency
|
|
|
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
269.9 |
277.1 |
265.9 |
|
1 074 |
|
Operating Income, bln rub |
|
|
65.0 |
66.1 |
58.0 |
|
253.6 |
|
EBITDA, bln rub |
? |
|
91.8 |
80.2 |
226.1 |
|
469.8 |
|
Net profit, bln rub |
? |
|
60.3 |
54.6 |
106.1 |
|
266.8 |
|
|
OCF, bln rub |
? |
|
79.0 |
68.1 |
13.4 |
|
251.0 |
|
CAPEX, bln rub |
? |
|
14.9 |
6.78 |
5.61 |
|
33.8 |
|
FCF, bln rub |
? |
|
64.1 |
61.3 |
7.81 |
|
217.2 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
153.4 |
158.5 |
159.0 |
|
619.4 |
|
Cost of production, bln rub |
|
|
51.5 |
52.6 |
48.9 |
|
200.6 |
|
R&D, bln rub |
|
|
43.8 |
40.5 |
42.1 |
|
167.2 |
|
Interest expenses, bln rub |
|
|
9.76 |
3.77 |
80.7 |
|
94.2 |
|
|
Assets, bln rub |
|
|
1 673 |
1 704 |
1 697 |
|
1 697 |
|
Net Assets, bln rub |
? |
|
1 503 |
1 536 |
1 540 |
|
1 540 |
|
Debt, bln rub |
|
|
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Cash, bln rub |
|
|
758.6 |
844.3 |
820.4 |
|
820.4 |
|
Net debt, bln rub |
|
|
-758.6 |
-844.3 |
-820.4 |
|
-820.4 |
|
|
Ordinary share price, rub |
|
|
331.2 |
247.5 |
245.7 |
|
381.0 |
|
Number of ordinary shares, mln |
|
|
45.5 |
45.6 |
45.4 |
|
45.4 |
|
|
Market cap, bln rub |
|
|
15 079 |
11 280 |
11 146 |
|
17 288 |
|
EV, bln rub |
? |
|
14 321 |
10 436 |
10 326 |
|
16 467 |
|
Book value, bln rub |
|
|
1 381 |
1 413 |
1 417 |
|
1 417 |
|
|
EPS, rub |
? |
|
1.33 |
1.20 |
2.34 |
|
5.88 |
|
FCF/share, rub |
|
|
1.41 |
1.35 |
0.17 |
|
4.79 |
|
BV/share, rub |
|
|
30.3 |
31.0 |
31.2 |
|
31.2 |
|
|
EBITDA margin, % |
? |
|
34.0% |
28.9% |
85.0% |
|
43.7% |
|
Net margin, % |
? |
|
22.4% |
19.7% |
39.9% |
|
24.8% |
|
FCF yield, % |
? |
|
1.66% |
2.33% |
1.95% |
|
1.26% |
|
ROE, % |
? |
|
9.08% |
14.2% |
17.3% |
|
17.3% |
|
ROA, % |
? |
|
8.16% |
12.8% |
15.7% |
|
15.7% |
|
|
P/E |
? |
|
110.5 |
51.8 |
41.8 |
|
64.8 |
|
P/FCF |
|
|
60.4 |
42.9 |
51.3 |
|
79.6 |
|
P/S |
? |
|
14.6 |
10.7 |
10.4 |
|
16.1 |
|
P/BV |
? |
|
10.9 |
7.98 |
7.87 |
|
12.2 |
|
EV/EBITDA |
? |
|
34.3 |
33.7 |
22.0 |
|
35.1 |
|
Debt/EBITDA |
|
|
-1.82 |
-2.72 |
-1.75 |
|
-1.75 |
|
|
R&D/CAPEX, % |
|
|
294.0% |
596.7% |
750.4% |
|
495.3% |
|
|
CAPEX/Revenue, % |
|
|
5.52% |
2.45% |
2.11% |
|
3.14% |
|
| ABIOMED shareholders |
